Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
Volume 0.28M
Average 0.21M
NERV Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Minerva Neurosciences, Inc.NASDAQ: NERV
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables turns negative
Q2 FY2026 accounts payables was -$693.74K, compared with $256.85K a year earlier. Trailing-twelve-month accounts payables was $423.37K. Over 3 fiscal years it compounded at +6.2% a year.
Context
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$693.74K or moves back toward the trailing-twelve-month quarterly average of $105.84K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (1.06M) USD
- Year-over-year change
- -436.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.06M) | -436.3% |
| FY2024 | 2024-12-31 | (197.48K) | -123.6% |
| FY2023 | 2023-12-31 | 835.65K | +194.6% |
| FY2022 | 2022-12-31 | (883.55K) | -203.0% |
| FY2021 | 2021-12-31 | 857.6K | — |
Accounts Payables vs competitors
How NERV compares with its peers on the latest reported figures
- NERV's LTM Jun 2026 accounts payables of $423.37K is the 3rd largest of the 4 companies compared; the peer median is $540K.
- Over three fiscal years its annual growth of +6.2% compares with a peer median of +36.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $3.18M | +16967.7% | +36.9% | — | |
| LTM Mar 2026 | $540K | +871.4% | — | 62.9% | |
| LTM Jun 2026 | $423.37K | — | +6.2% | — | |
NRXSNeurAxis, Inc. | LTM Mar 2026 | $229.72K | -67.3% | — | 5.4% |
| Peer median (excluding NERV) | $540K | +871.4% | +36.9% | 34.2% | |
Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.91M) | (32.11M) | (30.01M) | 1.44M | (293.42M) |
| Depreciation & Amortization | 101.79K | 8.51K | 30.98K | 22.47K | 5.44M |
| Deferred Income Tax | (1.8M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.22M | 4.11M | 1.97M | 1.33M | 1.33B |
| Change in Working Capital | 259.34K | (4.06M) | 4.94M | (320.6K) | (632.35K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 857.6K | (883.55K) | 835.65K | (197.48K) | (1.06M) |
| Other Working Capital | (598.27K) | (3.18M) | 4.1M | (123.13K) | 426.67K |
| Other Non-Cash Items | 21.53M | 7.41M | 8.28M | (22.02M) | (14.55B) |
| Operating Cash Flow | (24.6M) | (24.65M) | (14.78M) | (19.55M) | (13.51B) |
| Capital Expenditures | 0 | (16.33K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (16.33K) | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 20M | 0 | 74.45M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 60M | (5) | (396.29K) | 0 | 74.38B |
| Financing Cash Flow | 60M | (5) | 19.6M | 0 | 74.45B |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 35.4M | (24.66M) | 4.82M | (19.55M) | 60.94B |
| Free Cash Flow | (24.6M) | (24.66M) | (14.78M) | (19.55M) | (13.51B) |
Minerva Neurosciences, Inc.
NASDAQ:NERV
Intrinsic Alpha fair value
Locked
Current Price
$2.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.